In vivo veritas: Bcl-2 and Bcl-X(L) mediate tumor cell resistance to chemotherapy

Drug Resistance Updates

Volumn 3, Issue 3, 2000, Pages 149-154

  Fujita, Naoya ^a   Tsuruo, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CAMPTOTHECIN; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; VINCRISTINE;

APOPTOSIS; CELL SURVIVAL; CHEMOTHERAPY; CLONOGENIC ASSAY; DNA DAMAGE; DRUG PROTEIN BINDING; ENVIRONMENTAL FACTOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR RESISTANCE;

EID: 0033853183     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0142     Document Type: Article

References (55)

1. Mechanisms of multidrug resistance and implications for therapy
2. Apoptosis and the dilemma of cancer chemotherapy
3. Apoptosis in the pathogenesis and treatment of disease
4. Bcl-2 family: Life-or-death switch
5. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
6. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
7. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system
8. Activation and role of caspases in chemotherapy-induced apoptosis
9. Conversion of Bcl-2 to a Bax-like death effector by caspases
10. Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: Evidence for a caspase-mediated, proteolytic inactivation of Bcl-2
11. Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis
12. Modulation of cell death by Bcl-X(L) through caspase interaction
13. Acceleration of apoptotic cell death after the cleavage of Bcl-X(L) protein by caspase-3-like proteases
14. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis
15. The proto-oncogene Bcl-2 and its role in regulating apoptosis
16. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
17. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions
18. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2
19. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing
20. Double identity for proteins of the Bcl-2 family
21. X-ray and NMR structure of human Bcl-X(L), an inhibitor of programmed cell death
22. Structure of Bcl-X(L)-Bak peptide complex: Recognition between regulators of apoptosis
23. Caspase-mediated cleavage of p21(Wafl/cipl) converts cancer cells from growth arrest to undergoing apoptosis
24. Cleavage of p21(Cipl/Wafl) and p27(Kipl) mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade
25. Model for p53-induced apoptosis
26. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins
27. P21(Wafl/kCipl) acts in synergy with Bcl-2 to confer multidrug resistance in a camptothecin-selected human lung cancer cell line
28. Involvement of the bcl-2 gene in human follicular lymphoma
29. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
30. Expression of bcl-x(L) can confer a multidrug resistance phenotype
31. Bcl-2 and Bcl-X(L) can differentially block chemotherapy-induced cell death
32. Molecular thanatopsis: A discourse on the BCL2 family and cell death
33. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
34. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
35. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
36. Prognostic value of bcl-2 expression in invasive breast cancer
37. Overexpression of Bcl-X(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model
38. Expression of the apoptosis-suppressing protein Bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification
39. Social controls on cell survival and cell death
40. The tumor microenvironment as a determinant of drug response and resistance
41. Suppression of T-lymphoma cell apoptosis by monoclonal antibodies raised against cell surface adhesion molecules
42. Involvement of CD45 in adhesion and suppression of apoptosis of mouse malignant T-lymphoma cells
43. Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression
44. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells
45. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors
46. Cellular survival: A play in three Akts
47. The P13K-PDK1 connection: More than just a road to PKB
48. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
49. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
50. Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis
51. Reversing drug resistance in bcl-2 expressing tumor cells by depleting glutathione
52. Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells
53. Novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
54. The c-1AP-1 and c-1AP-2 proteins are direct inhibitors of specific caspases
55. A human IAP-family gene, apollon, expressed in human brain cancer cells